兴齐眼药2024年净利润同比增长40.84% 将继续加大研发投入力度

Core Insights - The company, Xingqi Eye Medicine, reported a revenue of 1.943 billion yuan for 2024, representing a year-on-year growth of 32.42% [1] - The net profit reached 338 million yuan, with a year-on-year increase of 40.84% [1] - The company has a diverse product line in the ophthalmic drug sector, with 60 approved ophthalmic drug registrations, 38 of which are included in the medical insurance directory [1] Financial Performance - Revenue for 2024: 1.943 billion yuan, up 32.42% year-on-year [1] - Net profit: 338 million yuan, up 40.84% year-on-year [1] - Basic earnings per share: 1.94 yuan [1] - Proposed distribution plan: 4 shares bonus for every 10 shares and a cash dividend of 10 yuan (tax included) [1] Product Development - The company has received a drug registration certificate for atropine sulfate eye drops, with no similar products currently available in the domestic market for myopia [2] - The company is advancing multiple clinical trials, including for cyclosporine eye drops and SQ-22031 eye drops, which are intended for dry eye syndrome and neurotrophic keratitis [2] - The low-concentration atropine sulfate eye drops are prescription medications available through qualified hospitals and optical centers [3] R&D Strategy - The company plans to increase R&D investment in 2025 to expand its product line in the ophthalmic sector [3] - It aims to enhance its portfolio in the treatment of retinal diseases through various innovative drug delivery technologies [3] - The R&D strategy will focus on independent innovation and collaborative development with academic institutions [3]